MedPath

BlueWillow Biologics

🇰🇷South Korea
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:2

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults

Phase 1
Completed
Conditions
Influenza, Pandemic
First Posted Date
2022-05-31
Last Posted Date
2024-08-22
Lead Sponsor
BlueWillow Biologics
Target Recruit Count
40
Registration Number
NCT05397119
Locations
🇺🇸

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, United States

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults

Phase 1
Completed
Conditions
Anthrax
First Posted Date
2019-11-01
Last Posted Date
2022-05-18
Lead Sponsor
BlueWillow Biologics
Target Recruit Count
84
Registration Number
NCT04148118
Locations
🇺🇸

Johnson County Clin-Trial, Lenexa, Kansas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.